Skip to main content

Diagnostic Hybrids Licenses HIV PGx Technology from Case Western

NEW YORK (GenomeWeb News) – Diagnostic Hybrids this week announced that it has licensed exclusive worldwide rights from Case Western Reserve University to pharmacogenomics test technology for monitoring HIV treatment.

The Athens, Ohio-based firm licensed novel yeast-based virus cloning technology invented by Eric Arts, an associate professor of medicine in the division of infectious diseases, department of medicine, at Case Western Reserve School of Medicine. It said that the technology can monitor the success of HIV treatments by determining drug resistance and disease "strength" of the virus.

Diagnostic Hybrids and Case Western were awarded a $5 million grant last year from the Ohio Third Frontier Biomedical Research and Commercialization Program to accelerate commercial development of a suite of diagnostic products for HIV, hepatitis, and influenza using the yeast vector technology.

Financial and other terms of the license were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.